ADC Therapeutics (ADCT) Payables (2019 - 2026)

ADC Therapeutics has disclosed Payables across 8 years of filings, most recently posting $12.8 million for Q2 2026.

• In Q2 2026, Payables rose 32.71% year-over-year to $12.8 million; the TTM figure through Jun 2026 stood at $12.8 million (up 32.71% YoY), while the FY2025 annual figure was $9.2 million, down 49.11% from the prior year.
• Payables came in at $12.8 million for Q2 2026 at ADC Therapeutics, up from $5.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $25.6 million in Q2 2023 to a low of $5.3 million in Q1 2026.
• Average Payables over 5 years is $15.7 million, with a median of $15.0 million recorded in 2023.
• Year-over-year, Payables surged 105.5% in 2022 and sank 66.04% in 2026.
• Over 5 years, Payables stood at $24.8 million in 2022, then sank by 37.28% to $15.6 million in 2023, then grew by 15.8% to $18.0 million in 2024, then sank by 49.11% to $9.2 million in 2025, then jumped by 39.08% to $12.8 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $12.8 million in Q2 2026, $5.3 million in Q1 2026, and $9.2 million in Q4 2025.